Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 5/20 | 0.38 |
| ▸ | DNM2 | P50570 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 5/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277450 | 1.00 | BRD4 (0.38) | BRD4ATAD2DNM2KDM4EALDH1A1 | |
| SCHEMBL1277902 | 0.90 | BRD4 (0.39) | BRD4ATAD2PIM1PIM2 | |
| SCHEMBL1277897 | 0.90 | BRD4 (0.39) | BRD4ATAD2PIM1PIM2 | |
| SCHEMBL1277833 | 0.88 | BRD4 (0.38) | BRD4ATAD2KDM4EPIM1PIM2 | |
| SCHEMBL1277831 | 0.88 | BRD4 (0.38) | BRD4ATAD2KDM4EPIM1PIM2 | |
| SCHEMBL1278146 | 0.87 | BRD4 (0.38) | BRD4ATAD2PIM1PIM2 | |
| SCHEMBL1278150 | 0.87 | BRD4 (0.38) | BRD4ATAD2PIM1PIM2 | |
| SCHEMBL2930374 | 0.87 | BRD4 (0.41) | BRD4ATAD2KDM4EPIM1PIM2 | |
| SCHEMBL1277794 | 0.86 | DNM2 (0.32) | DNM2 | |
| SCHEMBL1277796 | 0.86 | BRD4 (0.38) | BRD4ATAD2PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801965-B | Indole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2014-07-30 | — | — | CN | claimed |
| EP-2178869-B1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2013-06-12 | — | — | EP | claimed |
| US-8222414-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2012-07-17 | — | — | US | claimed |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | claimed |
| EP-2220081-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2010-08-25 | — | — | EP | claimed |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | US | claimed |
| CN-101801965-A | Indole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2010-08-11 | — | — | CN | claimed |
| EP-2178869-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | claimed |
| WO-2009025477-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | claimed |
| US-8889691-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2014-11-18 | — | — | US | disclosed |
| CN-101801965-B | Indole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2014-07-30 | — | — | CN | disclosed |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| US-8569307-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-10-29 | — | — | US | disclosed |
| EP-2178869-B1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2013-06-12 | — | — | EP | disclosed |
| CN-101801965-A | Indole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2010-08-11 | — | — | CN | disclosed |
| EP-2178869-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009025477-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | BRD4 2348/4885ATAD2 2935/4885DNM2 2263/4885 |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | BRD4 2348/4885ATAD2 2935/4885DNM2 2263/4885 |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCK, GCKR, HK1 | BRD4 3674/4885ATAD2 2052/4885DNM2 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.